Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in North Carolina: - Cone Health Cancer Center at Asheboro — Asheboro, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- AdventHealth Infusion Center Asheville — Asheville, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Cone Health MedCenter Asheboro — Asheboro, North Carolina
- Cone Health Cancer Center at Alamance Regional — Burlington, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in North Carolina: - Levine Cancer Institute ( Site 0083) — Charlotte, North Carolina
- Cape Fear Valley Health System ( Site 0136) — Fayetteville, North Carolina
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in North Carolina: - Regional Medical Oncology Center_Wlson — Wilson, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in North Carolina: - Pardee Cancer Center — Hendersonville, North Carolina
- Carolina Cancer Research Center — Wilson, North Carolina
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in North Carolina: - Messino Cancer Center — Asheville, North Carolina
- Duke Cancer Institute — Durham, North Carolina
- UNC Central Investigational Drug Services — Morrisville, North Carolina
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Sites in North Carolina: - Novant Health Presbyterain Medical Center — Charlotte, North Carolina
- Novant Health Forsyth Medical Center — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
- Duke Women's Cancer Care Raleigh — Raleigh, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in North Carolina: - UNC Hospitals, University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in North Carolina: - University of North Carolina Medical Center — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in North Carolina: - Wake Forest University at Clemmons — Clemmons, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in North Carolina: - Atrium Health Wake Forest Baptist - Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in North Carolina: - The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting Industry
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmaco…
Sponsor: Incyclix Bio
NCT ID: NCT05735080
Sites in North Carolina: - Levine Cancer Institute (LCI)- Atrium Health — Charlotte, North Carolina
- Duke Cancer Center/ DUMC — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative…
Sponsor: Kathy Miller
NCT ID: NCT05846789
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or with…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT02422641
Sites in North Carolina: - Comprehensive Cancer Center at Wake Forest University (CCCWFU) — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of…
Sponsor: University of Washington
NCT ID: NCT06179303
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an obs…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT04677816
Sites in North Carolina: - Wake Forest Baptist Health Sciences — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-re…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06727773
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina